Status:
COMPLETED
Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis
Lead Sponsor:
Allergopharma GmbH & Co. KG
Conditions:
Grass Pollen Allergy
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The trial is performed to assess efficacy and safety of the Grass Pollen Allergoid in Allergic Rhinoconjunctivitis
Detailed Description
Pollen allergoids are prepared by chemical modification of partially purified native allergen aqueous extracts that have been depleted of components with a molecular mass of less than 5000 Daltons by ...
Eligibility Criteria
Inclusion
- Positive Skin Prick test to grass pollen
- Positive RAST to grass pollen
- Positive specific provocation test to grass pollen
Exclusion
- Serious chronic diseases
- Other perennial allergies
Key Trial Info
Start Date :
November 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
154 Patients enrolled
Trial Details
Trial ID
NCT00263601
Start Date
November 1 2001
End Date
August 1 2010
Last Update
June 5 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allergopharma GmbH & Co. KG
Reinbek, Germany, 21465